What's Happening?
The Health Resources and Services Administration (HRSA) has revived its 340B Rebate Model Pilot Program, announcing a revised version on July 31, 2026, and formalizing it in the Federal Register on August 3, 2026. This marks HRSA's second attempt in just
over a year to transition a subset of 340B drugs from upfront discounts to retrospective manufacturer rebates. Under the revised pilot, participating covered entities will purchase affected drugs at wholesale acquisition cost (WAC) and then submit claims to manufacturers for a rebate equal to the difference between WAC and the 340B ceiling price. Manufacturers must submit rebate plans to HRSA by August 24, 2026, with approvals expected by September 24, 2026, and the pilot launching on January 1, 2027, for at least one year. In response, on August 5, 2026, the Senate 340B Bipartisan Working Group, including Senators Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine, John Boozman, and John Hickenlooper, introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). This bill aims to preserve the traditional point-of-purchase discount model as the default and sunset HRSA's pilot program within one year of enactment.
Why It's Important?
The revival of HRSA's 340B Rebate Model Pilot Program and the immediate congressional response highlight a significant conflict over the future of the 340B drug pricing program, which provides discounted drugs to eligible healthcare organizations. The shift from upfront discounts to retrospective rebates could have substantial financial and operational impacts on health systems, particularly safety-net providers, by altering cash flow and increasing administrative burdens. While HRSA asserts the pilot will not destabilize entities, hospital groups sharply dispute this. The SUSTAIN 340B Act, introduced by a bipartisan Senate working group, directly challenges HRSA's approach, aiming to maintain the current discount model and establish an independent data clearinghouse for claims data and duplicate discount identification. This legislative counter-move underscores the deep divisions and high stakes involved, as the 340B program is crucial for many hospitals and clinics serving vulnerable populations, influencing their ability to provide care and manage drug costs.
What's Next?
Health systems are now navigating three distinct and potentially conflicting paths for 340B reform. HRSA's Rebate Model Pilot is proceeding with binding near-term deadlines, including manufacturer plans due by August 24, 2026, and a launch date of January 1, 2027. This means health systems must prepare for its implementation unless a court intervenes or Congress acts swiftly. Concurrently, Senator Cassidy's discussion draft, which offers covered entities a choice of discount mechanisms, is open for stakeholder comments until August 28, 2026. The newly introduced SUSTAIN 340B Act, aiming to block the rebate model and establish a clearinghouse, will move through the legislative process. Health systems are advised to assess their program exposure, evaluate cash-flow implications, strengthen claims readiness, and monitor HRSA approval timing. Engagement with legislative and regulatory channels, including submitting comments on the Cassidy draft, is crucial as the future of 340B reform remains an open question, with multiple potential outcomes.
Beyond the Headlines
The ongoing struggle over the 340B program's structure reveals deeper tensions within the U.S. healthcare system, particularly concerning drug pricing, access to care for underserved communities, and the financial viability of safety-net providers. The debate highlights the complex interplay between federal agencies, pharmaceutical manufacturers, and healthcare providers. HRSA's push for a rebate model, despite previous legal challenges, suggests a persistent effort to reform the program's mechanics, potentially driven by concerns over program integrity or manufacturer interests. Conversely, the bipartisan congressional effort to preserve the discount model underscores a legislative commitment to protecting the financial benefits that covered entities derive from 340B, which are often reinvested into patient care. This situation could set a precedent for how drug pricing programs are administered and reformed in the future, potentially influencing the balance of power among key healthcare stakeholders and ultimately impacting patient access to affordable medications.
